This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Small-Cap Winners & Losers

Small-cap stocks underperformed the tumbling broad indices for the second straight session Tuesday despite several bouts of good news out of the health-care sector.

Xoma (XOMA - Get Report), for instance, vaulted 17.5% after saying it has licensed to Pfizer (PFE) nonexclusive rights to its patented antibody technology. Pfizer will pay the Berkeley, Calif., company $30 million cash upfront for the bacterial cell expression technology in addition to "milestone, royalty and other fees on future sales of all products subject to this license, including products currently in late-stage clinical development." Xoma shares soared 40 cents to $2.68. Pfizer slipped 1.5% to $24.39.

Omrix Biopharmaceuticals (OMRI) jumped 16.5% to $33.86 after the Food and Drug Administration approved the New York-based company's Evithrom product -- a blood-clotting protein indicated for use during surgery.

Elsewhere in the health-care market, Advanced Life Sciences (ADLS) said the FDA granted orphan drug designation (for drugs that treat rare diseases) to its ALS-357 compound for the topical treatment of metastatic melanoma, a type of skin cancer.

That designation makes ALS-357 eligible for seven-year exclusivity on approval, in addition to potential tax credits, R&D grant funding and other benefits. Shares of the Woodridge, Ill., company climbed 6.7% to $1.76.

Perceptron (PRCP - Get Report), which makes measurement and inspection technology primarily for the automotive industry, also had a quick rise on positive fiscal fourth-quarter financials. The Plymouth, Mich., company said it swung to a profit of $2.3 million, or 26 cents a share, on sales that surged 61.3% year over year to $23.4 million. Shares lately gained 11.7% to $11.62.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ADLS $0.01 -1.34%
PRCP $7.72 -1.00%
SAFM $66.88 -3.30%
XOMA $0.95 -4.60%
AAPL $111.73 0.12%


Chart of I:DJI
DOW 17,081.89 -49.97 -0.29%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,796.6090 -42.0340 -0.87%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs